“The American taxpayer shouldn’t finance risky experiments when Big Pharma is already gorging on pandemic profits.”
When Washington walks away but global coalitions rush in, everyday Americans need to ask what’s really going on behind the next big mRNA ‘solution.’ This week, the notorious biotech giant Moderna found itself blessed with a rescue rope: the globalist-run Coalition for Epidemic Preparedness Innovations (CEPI) is pledging up to $54.3 million to fund a pivotal phase 3 trial for Moderna’s H5 mRNA bird flu vaccine, mRNA-1018. CEPI-a powerful coalition with deep ties to international pharmaceutical interests-didn’t hesitate to step into the void after the Biden administration’s Department of Health and Human Services (HHS) abruptly canceled a $700 million taxpayer-backed contract with Moderna in May 2025. It’s a move raising eyebrows and tough questions all across conservative America.
The mainstream media may celebrate this last-minute lifeline as good news for ‘pandemic preparedness,’ but ask yourself-if our own health officials bailed, why are shadowy global health bodies so eager to push forward with controversial mRNA technology for pandemics that have yet to materialize? And whose interests are being protected: yours, or corporate and globalist agendas?
“Moderna’s stock might be soaring, but faith in public health authorities and Big Pharma plummets every time bureaucrats play politics with pandemic dollars.”
Globalists Pick Up Where Robert F. Kennedy Jr. Leaves Off
The cracks in government trust are impossible to ignore. Americans have watched as the Biden administration, always quick to bow to political winds, abruptly pulled its massive financial support for Moderna’s ambitious mRNA-1018 bird flu project. The reason for walking away? None other than HHS Secretary Robert F. Kennedy Jr., who went on the record with a heavy dose of skepticism toward the entire experimental mRNA vaccine craze swirling in elite international health circles. Kennedy, never shy about flexing his own ideological brand, signaled he’d rather redirect U.S. funds “to other public health priorities than repeat past mistakes with under-tested mRNA shots”-a thinly veiled swipe at both Big Pharma and years of rushed vaccine development.
According to FactCheck.org, Kennedy stated the technology is ‘under-tested’ and flatly refused to bankroll ‘risky experiments’ with American dollars.
Is it any wonder that American parents, business owners, and community leaders are looking at this arrangement with deep suspicion? In the wake of the disastrous COVID-19 vaccine mandates and endless flip-flops from the CDC, the idea of jumping into another mRNA vaccine for a hypothetical H5 bird flu ‘emergency’ feels less like prep and more like ploy. In the words of social media commentator @LibertyMommaUSA, “Once again, out-of-touch globalists try to do what Biden’s team wouldn’t dare-rush an untested technology on the world when Americans have had enough.” This tweet quickly racked up over 35,000 likes and 20,000 retweets within hours, demonstrating just how little trust remains in these bureaucratic games.
“The Biden administration is dodging responsibility, but unelected global influencers are making American biotech their own playground.”
Pandemic Gold Rush: What’s at Stake With CEPI, Moderna, and the 100-Day Mission
Follow the money-and the power. As Moderna courts European regulators to get mRNA-1018 across the finish line, the game plan is nothing short of audacious. The company’s CEO Stéphane Bancel is touting this as a mission for global safety, claiming mRNA shots can counter any pandemic flu strain thrown at the world. “mRNA technology can play a vital role in addressing emerging health threats quickly and effectively,” Bancel told Reuters, emphasizing the company’s commitment to pandemic preparedness and the role of cutting-edge tech in the face of new viral threats.
But while Moderna is busy positioning itself as a savior, the real stakes are much higher-and far more political. CEPI, the same organization that pumped billions into the COVID-19 vaccine gold rush and funded high-profile efforts against Ebola and Zika, is back with another big checkbook. Their public pledge-at least 20% of Moderna’s future pandemic output for low- and middle-income countries-is being spun as humanitarian, but critics see it as carving out profit-friendly new markets overseas, all while pushing for speed over rigorous long-term safety. Notably, data from Moderna’s seasonal influenza studies-still ongoing and with little recent transparency-will be slipped straight into the H5 approval process, amplifying the controversy.
“CEPI threw billions at COVID shots-why should we expect a different result when the same playbook is being run on bird flu?”
With late-stage trials set to begin in early 2026-conveniently, just before the next major election cycle-observers wonder if the timing is intended to shield globalist health policy from domestic scrutiny while U.S. voters have their eyes elsewhere.
Americans Want Answers: Will mRNA Bird Flu Jabs Become the Next Mandate?
If the U.S. won’t fund it, why should Americans trust it? We’ve already seen a tidal wave of justified pushback to heavy-handed mandates, rushed clinical protocols, and the political favoritism showered on pharmaceutical giants since the earliest days of COVID. With bird flu hovering at the edge of the news cycle, many can’t help but wonder: Are we witnessing the build-up for another pandemic panic, tailor-fit for corporate gain?
The process now has all the classic warning signs: key political figures hedging their support, international actors calling the shots, and the biggest players in global pharma standing to make billions-no matter what. Moderna’s case is no exception; they’re banking big on data from their ongoing seasonal influenza vaccine trials to grease the wheels of regulatory approval for this untested H5 jab. And even as skepticism grows, CEPI’s machine keeps whirring, determined to meet their much-hyped ‘100 Days Mission’-the bold vision of rolling out vaccines worldwide within 100 days of any new outbreak, regardless of real-world consequence.
“Why is it always American ingenuity-and American data-that gets pawned off on the world, but the safety concerns get downplayed right here at home?”
While some in Washington recuse themselves from the murky politics of pandemic ‘preparedness,’ CEPI and their biotech partners are banking on short public memory and long profit horizons. The looming question for voters in 2026 is clear: will they demand accountability and transparency before the next pharmaceutical experiment lands on your doorstep-or will global players pull the strings as usual?
